Palvella Therapeutics, Inc. PVLA
Regular-session close
After hours · Nov 20, 4:26 PM ET
- YTD
- +36.48%
- 1 year
- +56.05%
5D -14.14 (-9.01%)
- Market cap
- 2.09B
- EPS (ttm)
- -5.53
- Shares out
- 14.62M
- Forward P/E
- -18.77
- YTD return
- +36.48%
- 1-year return
- +56.05%
- 50-day average
- 142.96
- 200-day average
- 131.76
- Enterprise value
- 1.92B
- Volume
- 192.67K
- Avg volume
- 239.93K
- Open
- 143.10
- Previous close
- 145.77
- Day's range
- 142.22 – 148.69
- 52-week range
- 76.43 – 175.92
- Analysts
- Strong Buy
- Price target
- 233.44 (+63.4%)
- Earnings date
- Mar 30, 2027
Key statistics
- Price / book
- 10.54
- Free cash flow
- -27.99M
- Total cash
- 236.68M
- Total debt
- 25.41M
- Return on equity
- -63.39%
- Short % of float
- 20.11%
Fundamental scorecard
3 of 25 checks passed on PVLA’s reported financials
3of 25 checks passed
- Value 0 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 207.00
- Target (mean)
- 233.44
- Target (high)
- 267.00
- Strong buy0
- Buy17
- Hold0
- Sell0
- Strong sell0
Next earnings
Mar 30, 2027
Expected Mar 30, 2027. Consensus EPS estimate -1.93.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 30, 2027 | Dec 30, 2026 | -1.95 | — | — | — |
| Nov 5, 2026 | Sep 30, 2026 | -1.78 | -1.70 | +0.08 | +4.49% |
| Aug 4, 2026 | Jun 30, 2026 | -1.17 | -1.52 | -0.35 | -29.91% |
| May 7, 2026 | Mar 31, 2026 | -0.90 | -1.20 | -0.30 | -33.33% |
| Mar 31, 2026 | Dec 31, 2025 | -0.91117 | -1.08 | -0.17 | -18.53% |
| Nov 11, 2025 | Sep 30, 2025 | -0.85 | -1.03 | -0.18 | -21.18% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 9, 2026 | Canaccord Genuity | main | Buy | Buy |
| Nov 6, 2026 | Oppenheimer | main | Outperform | Outperform |
| Oct 28, 2026 | Chardan Capital | main | Buy | Buy |
| Oct 16, 2026 | William Blair | init | — | Outperform |
| Oct 12, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Sep 21, 2026 | Chardan Capital | main | Buy | Buy |
About Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- palvellatx.com
News
HC Wainwright & Co. Reiterates Buy on Palvella Therapeutics, Maintains $246 Price Target
Palvella Therapeutics, Inc. (PVLA) Discusses QTORIN Docetaxel for Extramammary Pagets Disease Prepared Remarks Transcript
Palvella Therapeutics Announces QTORIN™ Docetaxel, a New QTORIN™ Program for the Treatment of Extramammary Paget's Disease (EMPD)
Palvella Therapeutics to Host Webcast to Introduce New QTORIN™ Program Leerink Partners Initiates Coverage On Palvella Therapeutics with Outperform Rating, Announces Price Target of $228
Palvella Therapeutics (NASDAQ:PVLA) Stock: Insider Jeffrey Martini Sells 6,250 Shares Canaccord Genuity Maintains Buy on Palvella Therapeutics, Raises Price Target to $243
Oppenheimer Maintains Outperform on Palvella Therapeutics, Raises Price Target to $232
Palvella Therapeutics Q3 2026 Earnings Call Transcript Palvella Therapeutics Q3 EPS $(1.70) Beats $(1.82) Estimate
Your note
Sign in to keep a note on PVLA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| GOIN KATHLEEN | Chief Operating Officer | Sale | Aug 18, 2026 | 0 |
| HERON ELAINE J | Director | Purchase | Feb 26, 2026 | 53,691 |
| JENKINS GEORGE M | Director | Sale | Oct 13, 2026 | 146,132 |
| KIRITSY CHRISTOPHER P | Director | Sale | Sep 1, 2026 | 250 |
| KORENBERG MATTHEW E | Chief Financial Officer | Conversion of Exercise of derivative security | Jun 11, 2026 | 1,000 |
| MARTINI JEFFREY | Officer | Sale | Nov 10, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Jennison Associates LLC | 7.54% | 1,101,652 | 157.37M | Sep 29, 2026 |
| Montanova Capital LLC | 7.15% | 1,044,898 | 149.26M | Sep 29, 2026 |
| Blackrock Inc. | 6.77% | 989,691 | 141.38M | Sep 29, 2026 |
| Frazier Life Sciences Management, L.P. | 6.04% | 882,400 | 126.05M | Sep 29, 2026 |
| First Light Asset Management, LLC | 5.02% | 734,086 | 104.86M | Sep 29, 2026 |
| State Street Corporation | 4.27% | 624,879 | 89.26M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.66% | 388,390 | 55.48M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.48% | 362,314 | 51.76M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.11% | 308,699 | 44.10M | Sep 29, 2026 |
| Federated Hermes Equity Funds-Federated Hermes Kaufmann Fund | 1.89% | 276,556 | 39.51M | Jul 30, 2026 |
| MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund | 1.58% | 231,484 | 33.07M | Jun 29, 2026 |
| PRIMECAP Odyssey Funds-PRIMECAP Odyssey Aggressive Growth Fund | 1.45% | 212,225 | 30.32M | Sep 29, 2026 |
